Question 1

Has Patricia Gillar received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,656 in general payments to Patricia Gillar across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Patricia Gillar did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Patricia Gillar come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Lilly USA, LLC	22	$250
AstraZeneca	13	$203
Novo Nordisk	16	$187
Boehringer Ingelheim	13	$167
Mylan Specialty L.p.	8	$119
Shire North American Group Inc	6	$116
Amgen	8	$105
Mannkind Corporation	2	$71
Radius Health, Inc.	4	$59
Sanofi-aventis U.S. LLC	4	$56
AbbVie(2 entities)	3	$50
Corcept Therapeutics	2	$41
Amarin Pharma, Inc.	2	$35
GSK	2	$33
Supernus Pharmaceuticals, Inc.	2	$26
Pfizer	2	$26
Astellas Pharma US Inc	2	$26
Johnson & Johnson	2	$23
Merck	2	$23
Hikma Pharmaceuticals USA	1	$15
Sanofi Pasteur Inc.	1	$15
IBSA Pharma Inc.	1	$11

Patricia Gillar

Payments from drug & device makers

Who reported the general payments

How this compares

Other endocrinology, diabetes & metabolism in Georgetown